The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

DOD Ovarian Cancer Research Program FY20 funding opportunity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The FY20 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.

The FY 2020 Defense Appropriations Bill has not been signed into law—and although FY20 funds have not been appropriated for the Department of Defense Ovarian Cancer Research Program, the OCRP has published information to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities.

FY20 OCRP program announcements and general application instructions for the following award mechanism is posted on the Grants.gov website.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 
By Nicholas Richardson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account